Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers ("DFU")

Next Previous
X
Search
Trial Profile

Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers ("DFU")

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclerastide (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions; Registrational
  • Acronyms STRIDE-5
  • Sponsors Derma Sciences

    • Most Recent Events

    • 12 Nov 2015 According to a Derma Sciences media release, this study has been terminated based on futility determinations conducted by the Data Monitoring Committee (DMC) for the planned, pre-specified interim analyses regarding the primary efficacy endpoint.
    • 12 Nov 2015 Status changed from active, no longer recruiting to discontinued according to a Derma Sciences media release.
    • 02 Nov 2015 Planned End Date changed from 1 Oct 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top